BR112014006871A2 - fragmento de peptídeo antígeno, composição, métodos para tratar e/ou aliviar e/ou prevenir deficiências ou anormalidades, para produzir placas no cérebro, para induzir uma resposta imune contra proteína, e para produzir uma vacina, e, anticorpo ou uma mistura de anticorpo - Google Patents
fragmento de peptídeo antígeno, composição, métodos para tratar e/ou aliviar e/ou prevenir deficiências ou anormalidades, para produzir placas no cérebro, para induzir uma resposta imune contra proteína, e para produzir uma vacina, e, anticorpo ou uma mistura de anticorpoInfo
- Publication number
- BR112014006871A2 BR112014006871A2 BR112014006871A BR112014006871A BR112014006871A2 BR 112014006871 A2 BR112014006871 A2 BR 112014006871A2 BR 112014006871 A BR112014006871 A BR 112014006871A BR 112014006871 A BR112014006871 A BR 112014006871A BR 112014006871 A2 BR112014006871 A2 BR 112014006871A2
- Authority
- BR
- Brazil
- Prior art keywords
- producing
- antibody
- alleviating
- abnormalities
- vaccine
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 2
- 108010033276 Peptide Fragments Proteins 0.000 title 1
- 102000007079 Peptide Fragments Human genes 0.000 title 1
- 230000005856 abnormality Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 210000004556 brain Anatomy 0.000 title 1
- 230000007812 deficiency Effects 0.000 title 1
- 230000028993 immune response Effects 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| USPCT/US2011/052992 | 2011-09-23 | ||
| PCT/US2012/056728 WO2013044147A1 (en) | 2011-09-23 | 2012-09-21 | Vaccine therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014006871A2 true BR112014006871A2 (pt) | 2017-04-04 |
Family
ID=47018510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014006871A BR112014006871A2 (pt) | 2011-09-23 | 2012-09-21 | fragmento de peptídeo antígeno, composição, métodos para tratar e/ou aliviar e/ou prevenir deficiências ou anormalidades, para produzir placas no cérebro, para induzir uma resposta imune contra proteína, e para produzir uma vacina, e, anticorpo ou uma mistura de anticorpo |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20240270829A1 (pt) |
| EP (1) | EP2758071B1 (pt) |
| JP (1) | JP6110861B2 (pt) |
| KR (3) | KR102129220B1 (pt) |
| CN (2) | CN109847058A (pt) |
| AU (1) | AU2012312126B2 (pt) |
| BR (1) | BR112014006871A2 (pt) |
| CA (1) | CA2811188C (pt) |
| DK (1) | DK2758071T3 (pt) |
| EA (1) | EA032494B1 (pt) |
| ES (1) | ES2712951T3 (pt) |
| HU (1) | HUE041277T2 (pt) |
| IL (1) | IL231564A0 (pt) |
| MX (1) | MX350928B (pt) |
| MY (1) | MY169574A (pt) |
| PL (1) | PL2758071T3 (pt) |
| PT (1) | PT2758071T (pt) |
| SG (1) | SG11201400795UA (pt) |
| SI (1) | SI2758071T1 (pt) |
| TR (1) | TR201901846T4 (pt) |
| WO (1) | WO2013044147A1 (pt) |
| ZA (1) | ZA201402071B (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20150646A1 (es) | 2012-08-16 | 2015-05-21 | Ipierian Inc | Metodos de tratamiento de una tauopatia |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| NZ630610A (en) | 2014-02-14 | 2019-05-31 | Ipierian Inc | Tau peptides, anti-tau antibodies, and methods of use thereof |
| CA3118692A1 (en) | 2018-11-06 | 2020-05-14 | Alsatech, Inc. | Cell-based gene therapy for neurodegenerative diseases |
| TW202110425A (zh) | 2019-05-21 | 2021-03-16 | 瑞士商Ａｃ 免疫有限公司 | 抗Ａβ疫苗治療 |
| WO2024156912A1 (en) | 2023-01-26 | 2024-08-02 | Ac Immune Sa | Anti-abeta vaccine therapy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU9123998A (en) | 1997-08-28 | 1999-03-16 | Ajay North America | Methods and compositions for protecting plants and crops |
| MXPA05006940A (es) | 2002-12-24 | 2006-02-22 | Neurochem Int Ltd | Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide. |
| NZ567324A (en) * | 2003-02-01 | 2009-08-28 | Wyeth Corp | Active immunization to generate antibodies to soluble A-beta |
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| AR047062A1 (es) * | 2003-12-17 | 2006-01-04 | Wyeth Corp | Conjugados portadores de peptidos inmunogenicos a beta y metodos para producirlos |
| KR20070040824A (ko) * | 2004-07-30 | 2007-04-17 | 리나트 뉴로사이언스 코퍼레이션 | 아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용방법 |
| CN101330923B (zh) * | 2005-12-12 | 2015-01-07 | Ac免疫有限公司 | 治疗性疫苗 |
| WO2008156621A1 (en) * | 2007-06-12 | 2008-12-24 | Ac Immune S.A. | Monoclonal anti beta amyloid antibody |
| WO2010106127A2 (en) * | 2009-03-18 | 2010-09-23 | Ac Immune S.A. | Method for therapeutic use |
-
2011
- 2011-09-23 KR KR1020197008710A patent/KR102129220B1/ko active IP Right Grant
- 2011-09-23 KR KR1020137002631A patent/KR20160005380A/ko active Application Filing
- 2011-09-23 KR KR1020167021791A patent/KR20160099732A/ko active Application Filing
- 2011-09-23 CA CA2811188A patent/CA2811188C/en active Active
-
2012
- 2012-09-21 CN CN201910160828.6A patent/CN109847058A/zh active Pending
- 2012-09-21 PL PL12772616T patent/PL2758071T3/pl unknown
- 2012-09-21 PT PT12772616T patent/PT2758071T/pt unknown
- 2012-09-21 AU AU2012312126A patent/AU2012312126B2/en active Active
- 2012-09-21 EP EP12772616.4A patent/EP2758071B1/en active Active
- 2012-09-21 EA EA201400376A patent/EA032494B1/ru not_active IP Right Cessation
- 2012-09-21 DK DK12772616.4T patent/DK2758071T3/en active
- 2012-09-21 MX MX2014003325A patent/MX350928B/es active IP Right Grant
- 2012-09-21 ES ES12772616T patent/ES2712951T3/es active Active
- 2012-09-21 CN CN201280057432.5A patent/CN104039346A/zh active Pending
- 2012-09-21 JP JP2014532040A patent/JP6110861B2/ja active Active
- 2012-09-21 SG SG11201400795UA patent/SG11201400795UA/en unknown
- 2012-09-21 MY MYPI2014000851A patent/MY169574A/en unknown
- 2012-09-21 HU HUE12772616A patent/HUE041277T2/hu unknown
- 2012-09-21 TR TR2019/01846T patent/TR201901846T4/tr unknown
- 2012-09-21 BR BR112014006871A patent/BR112014006871A2/pt not_active Application Discontinuation
- 2012-09-21 WO PCT/US2012/056728 patent/WO2013044147A1/en active Application Filing
- 2012-09-21 SI SI201231487T patent/SI2758071T1/sl unknown
-
2014
- 2014-03-18 IL IL231564A patent/IL231564A0/en active IP Right Grant
- 2014-03-20 ZA ZA2014/02071A patent/ZA201402071B/en unknown
-
2023
- 2023-12-22 US US18/395,150 patent/US20240270829A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT2758071T (pt) | 2019-01-11 |
| SG11201400795UA (en) | 2014-10-30 |
| EA201400376A1 (ru) | 2014-09-30 |
| SI2758071T1 (sl) | 2019-01-31 |
| KR20160099732A (ko) | 2016-08-22 |
| EA032494B1 (ru) | 2019-06-28 |
| CA2811188C (en) | 2020-04-28 |
| IL231564A0 (en) | 2014-04-30 |
| MY169574A (en) | 2019-04-22 |
| WO2013044147A1 (en) | 2013-03-28 |
| AU2012312126A1 (en) | 2014-03-27 |
| NZ622653A (en) | 2015-12-24 |
| MX2014003325A (es) | 2014-05-21 |
| PL2758071T3 (pl) | 2019-08-30 |
| ES2712951T3 (es) | 2019-05-16 |
| KR102129220B1 (ko) | 2020-07-02 |
| TR201901846T4 (tr) | 2019-03-21 |
| EP2758071A1 (en) | 2014-07-30 |
| DK2758071T3 (en) | 2019-02-18 |
| CN104039346A (zh) | 2014-09-10 |
| CA2811188A1 (en) | 2013-03-23 |
| JP6110861B2 (ja) | 2017-04-05 |
| MX350928B (es) | 2017-09-26 |
| CN109847058A (zh) | 2019-06-07 |
| HUE041277T2 (hu) | 2019-05-28 |
| AU2012312126B2 (en) | 2016-11-10 |
| US20240270829A1 (en) | 2024-08-15 |
| ZA201402071B (en) | 2017-08-30 |
| KR20190035948A (ko) | 2019-04-03 |
| EP2758071B1 (en) | 2018-11-28 |
| KR20160005380A (ko) | 2016-01-15 |
| JP2014531455A (ja) | 2014-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014028476A2 (pt) | fragmento imunogênico de um polipeptídeo, polinucleotídeo isolado, composição farmacêutica imunogênica, métodos para tratar uma infecção, para gerar uma resposta imune em um sujeito, e para imunizar um sujeito | |
| WO2013068563A3 (en) | Antibody molecules having specificity for human ox40 | |
| BR112014006871A2 (pt) | fragmento de peptídeo antígeno, composição, métodos para tratar e/ou aliviar e/ou prevenir deficiências ou anormalidades, para produzir placas no cérebro, para induzir uma resposta imune contra proteína, e para produzir uma vacina, e, anticorpo ou uma mistura de anticorpo | |
| ZA201504952B (en) | Human antibodies to respiratory syncytial virus f protein and methods | |
| PT2663579T (pt) | Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização | |
| WO2013106834A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
| IL240689A0 (en) | Production methods for controlling the content of carbon-terminated lysine, galactose and sialic acid in recombinant proteins | |
| MX357965B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar. | |
| PL2917229T3 (pl) | Przeciwciała i ich fragmenty aktywowane przeciwko domenie alfa-3 białka HLA-G, sposoby i środki ich wytwarzania oraz ich zastosowania | |
| IL232219B (en) | Human or humanized antibodies against tar-dna-binding protein 43kda and their uses | |
| ZA201308461B (en) | Multiple antigen presenting immunogenic composition and methods and uses thereof | |
| WO2014113490A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
| NZ630881A (en) | Use of semaphorin-4d binding molecules for treatment of atherosclerosis | |
| SG11201505460WA (en) | Methods for reducing aggregate levels in protein preparations by treatment with thio-heterocyclic cations | |
| IL231894A0 (en) | Compounds and methods for enhancing innate immune responses | |
| MY165499A (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| EP2699263A4 (en) | METHOD FOR REDUCING AN UNWANTED IMMUNE RESPONSE TO A FOREIGN-LIKE IN A HUMAN PATIENT WITH ANTI-CD4 ANTIBODIES OR CD4-BINDING FRAGMENTS THEREOF OR CD4-BINDING MOLECULES | |
| BR112013018742A2 (pt) | cya-transportador de polipeptídeo(s) e use para induzir tanto as terapias e resposta imunitária profilática | |
| EP3024482A4 (en) | Methods for diagnosing and treating immune disease | |
| EP3076985C0 (en) | COMPOSITION COMPRISING PROBIOTICS CAPABLE OF OVEREXPRESSING CLPB PROTEIN FOR USE IN THE TREATMENT OF OBESITY | |
| EP2528939A4 (en) | RECOMBINANT PROTEINS FOR USE IN VACCINES, ANTIBODIES TO THESE PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC PROCEDURES THEREWITH | |
| HK1222184A1 (zh) | 免疫原性肽綴合物及以之誘導抗流感治療性抗體應答的方法 | |
| MX2013009529A (es) | Tratamiento de enfermedad de crohn con fistulas. | |
| EP2734160A4 (en) | HEATED COMPRESSION THERAPY SYSTEM AND METHOD | |
| BR112014032456A2 (pt) | métodos in vitro, composição farmacêutica, kit para realização do método e método para melhorar o efeito de tratamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |